AUROPHARMA · Aurobindo Pharma Limited · NSE · Filed 14 Aug · 1 min read

Aurobindo's Eugia Unit I gets US FDA Warning Letter after OAI status

The Eugia Pharma formulation facility, a subsidiary unit Aurobindo says contributes about 2% of group revenue, has escalated from Official Action Indicated to a Warning Letter, with no impact stated on current US supplies.

What was filed

Aurobindo Pharma informed the exchanges that Unit-I, a formulation manufacturing facility of Eugia Pharma Specialities Ltd. — a wholly owned subsidiary — has received a Warning Letter from the US FDA. The company framed this as a follow-on to its earlier disclosure that the unit had been placed under Official Action Indicated (OAI) status. The Warning Letter is the regulator's escalation subsequent to that OAI classification.

Stated impact

Per the filing, the company said there is no impact on existing supplies to the US markets from this facility, and described the unit as a small share of overall group revenue. Aurobindo added that it remains committed to working closely with the US FDA, continues to enhance compliance on an ongoing basis, and will keep the exchanges informed of further developments.

Unit I contribution to group revenue: ~2%

A Warning Letter marks a further step in an ongoing US FDA compliance matter at one subsidiary facility. The company states no impact on current US supplies and characterises the unit as a small revenue contributor, but the resolution timeline and any effect on future approvals from the site are not addressed in the filing.